Advertisement


Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

2022 ASCO Annual Meeting

Advertisement

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At this meeting, we were pleased to present a translational analysis from NRG Oncology. NRG Oncology is a cooperative group that ran a study called NRG-HN002. This was a study looking for a de-intensification arm for HPV positive oropharyngeal cancer patients to take forward into a phase three setting in HN002. We had two arms on the study, which were a chemo radiation arm to 60 gray with weekly cisplatin, as well as an IMRT alone arm that's delivered over five weeks. This translational study was a study of blood specimens that were taking at three pre-specified endpoints. Baseline prior to treatment, after two weeks of radiation therapy or chemo radiation delivery, and then at two to four weeks after the end of the treatment and the participation rates were actually quite good, even though it was a separate substudy. We had about 50% participation over the course of the study, maybe weighing to about 40% by the end of the study. But half of patients donated specimens and we were able to find a few things with three different hypotheses. First of all, at the pre-treatment baseline, we found that there was a weak to moderate correlation of the detection level of the HPV-DNA fragments, which our tumor tissue modified. A little bit more specific than regular cell-free DNA. We were able to find a weak to moderate correlation with the overall gross tumor burden. We also found that 10% of patients were undetectable at baseline for a variety of potential reasons, which were continued to explore, could be mismatch with true HPV mismatched to P16, could be characteristics of the samples which were collected in a national study, could be characteristics of the infection, whether integrated or not. We'll continue to investigate that. For the intro treatment sample at two weeks, after two weeks of treatment, we did find a variation in changes over the course of the study in patients. There was some heterogeneity in the pattern of DNA response, which was interesting to see, although the vast majority of patients ended up at undetectability by the completion of treatment at the post-treatment final time point, but it was interesting to see that variation and also to see that it wasn't necessarily true of all patients that they had continuous decreases in the fragments per ml. Although if you looked at the median level overall, the trend was downward throughout the course of treatment. And then at the post-treatment time point, what we found was that essentially there seemed to be an association that was statistically significant with PFS events, and that is pretty notable because the patients on this study generally did pretty well. And we had a relatively small number of PFS events, but they were associated with continued detectability by the end of treatment. I think what's important about this study on an operational and sort of national scale is that this was done in a large scale national study within the cooperative group setting. And so it really shows the feasibility of being able to conduct meaningful translational research within that setting. And also it gives us a pathway forward. We have been able to confirm with this study that the level of tumor tissue modified HPV-DNA is appearing to be prognostic for outcome. And the fact that we're able to do in this study moves us towards the ability to standardize and possibly do more meaningful research in the future that moves us towards not just prognostic, but predictive biomarker status and potential implementation and actionability. I want to thank all the patients and investigators who cooperated in this study, it was a great team effort. And thank NRG headquarters, especially operations, biospecimen resource and statistical group for their support.

Related Videos

Lymphoma

Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab maintenance, may set a new benchmark for patients aged 65 or older with mantle cell lymphoma. With a median progression-free survival of 6.7 years, the ibrutinib combination is more beneficial than currently used chemoimmunotherapy (approximately 1.5–3.5 years) (Abstract LBA7502).

Gynecologic Cancers
Immunotherapy

Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).

Breast Cancer

Ann H. Partridge, MD, MPH, and Kevin Kalinsky, MD, on Breast Cancer: Latest Findings on Fulvestrant or Exemestane With or Without Ribociclib

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Kevin Kalinsky, MD, of Winship Cancer Institute at Emory University, discuss phase II findings from the MAINTAIN trial, which showed a benefit in progression-free survival for patients with hormone receptor–positive/HER2-negative metastatic breast cancer when they switched to endocrine therapy and received ribociclib after disease progression on another CDK4/6 inhibitor (Abstract LBA1004).

Bladder Cancer

Shilpa Gupta, MD, on Urothelial Cancer: Defining Who Is 'Platinum-Ineligible'

Shilpa Gupta, MD, of the Cleveland Clinic Foundation, discusses an updated consensus definition for standard therapy and clinical trial eligibility for patients with metastatic urothelial cancer who are platinum-ineligible, criteria that are proposed to guide treatment recommendations for this population. This may be especially important now that the U.S. Food and Drug Administration has restricted the use of first-line pembrolizumab to those who are considered platinum-ineligible (Abstract 4577).

Advertisement

Advertisement



Advertisement